Your browser doesn't support javascript.
loading
The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance.
Gehre, Florian; Otu, Jacob; Kendall, Lindsay; Forson, Audrey; Kwara, Awewura; Kudzawu, Samuel; Kehinde, Aderemi O; Adebiyi, Oludele; Salako, Kayode; Baldeh, Ignatius; Jallow, Aisha; Jallow, Mamadou; Dagnra, Anoumou; Dissé, Kodjo; Kadanga, Essosimna A; Idigbe, Emmanuel Oni; Onubogu, Catherine; Onyejepu, Nneka; Gaye-Diallo, Aissatou; Ba-Diallo, Awa; Rabna, Paulo; Mane, Morto; Sanogo, Moumine; Diarra, Bassirou; Dezemon, Zingue; Sanou, Adama; Senghore, Madikay; Kwambana-Adams, Brenda A; Demba, Edward; Faal-Jawara, Tutty; Kumar, Samrat; Tientcheu, Leopold D; Jallow, Adama; Ceesay, Samba; Adetifa, Ifedayo; Jaye, Assan; Pallen, Mark J; D'Alessandro, Umberto; Kampmann, Beate; Adegbola, Richard A; Mboup, Souleymane; Corrah, Tumani; de Jong, Bouke C; Antonio, Martin.
Afiliação
  • Gehre F; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Otu J; Institute of Tropical Medicine, Antwerp, Belgium.
  • Kendall L; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Forson A; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Kwara A; University of Ghana Medical School, Accra, Ghana.
  • Kudzawu S; Korle-Bu Teaching Hospital, Accra, Ghana.
  • Kehinde AO; Warren Alpert Medical School of Brown University, Providence, RI, USA.
  • Adebiyi O; The Miriam Hospital, Providence, RI, USA.
  • Salako K; Korle-Bu Teaching Hospital, Accra, Ghana.
  • Baldeh I; College of Medicine, University of Ibadan, Ibadan, Nigeria.
  • Jallow A; University College Hospital, Ibadan, Oyo, 23402, Nigeria.
  • Jallow M; University College Hospital, Ibadan, Oyo, 23402, Nigeria.
  • Dagnra A; University College Hospital, Ibadan, Oyo, 23402, Nigeria.
  • Dissé K; National Public Health Laboratory Services, Banjul, The Gambia.
  • Kadanga EA; National Public Health Laboratory Services, Banjul, The Gambia.
  • Idigbe EO; National Public Health Laboratory Services, Banjul, The Gambia.
  • Onubogu C; Laboratoire National de Reference Mycobacteria, Lome, Togo.
  • Onyejepu N; Laboratoire National de Reference Mycobacteria, Lome, Togo.
  • Gaye-Diallo A; Laboratoire National de Reference Mycobacteria, Lome, Togo.
  • Ba-Diallo A; Nigerian Institute of Medical Research, Lagos, Nigeria.
  • Rabna P; Nigerian Institute of Medical Research, Lagos, Nigeria.
  • Mane M; Nigerian Institute of Medical Research, Lagos, Nigeria.
  • Sanogo M; Laboratoire Bactériologie Virologie Aristide Le Dantec Sénégal, Dakar, Senegal.
  • Diarra B; Laboratoire Bactériologie Virologie Aristide Le Dantec Sénégal, Dakar, Senegal.
  • Dezemon Z; National Institute of Public Health, Bissau, Guinea-Bissau.
  • Sanou A; National Institute of Public Health, Bissau, Guinea-Bissau.
  • Senghore M; SEREFO Program, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
  • Kwambana-Adams BA; SEREFO Program, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
  • Demba E; Centre Muraz and the National TB Program, Ouagadougou, Burkina Faso.
  • Faal-Jawara T; Centre Muraz and the National TB Program, Ouagadougou, Burkina Faso.
  • Kumar S; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Tientcheu LD; Microbiology and Infection Unit, Warwick Medical School, University of Warwick, Coventry, UK.
  • Jallow A; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Ceesay S; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
  • Adetifa I; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Jaye A; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Pallen MJ; Institute of Tropical Medicine, Antwerp, Belgium.
  • D'Alessandro U; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
  • Kampmann B; Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
  • Adegbola RA; National Tuberculosis/Leprosy Control Program, Banjul, The Gambia.
  • Mboup S; Health Services, Ministry of Health and Social Welfare, Banjul, The Gambia.
  • Corrah T; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • de Jong BC; Disease Control and Elimination, Medical Research Council Unit, Serrekunda, The Gambia.
  • Antonio M; Vaccines and Immunity Theme, Medical Research Council Unit The Gambia, Banjul, The Gambia.
BMC Med ; 14(1): 160, 2016 Nov 03.
Article em En | MEDLINE | ID: mdl-27806714
ABSTRACT

BACKGROUND:

Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data.

METHODS:

Following GCLP and laboratory training sessions, TB isolates were collected at sentinel referral sites between 2009-2013 and tested for first- and second-line drug resistance.

RESULTS:

From the analysis of 974 isolates, an unexpectedly high prevalence of multi-drug-resistant (MDR) strains was found in new (6 %) and retreatment patients (35 %) across all sentinel sites, with the highest prevalence amongst retreatment patients in Bamako, Mali (59 %) and the two Nigerian sites in Ibadan and Lagos (39 % and 66 %). In Lagos, MDR is already spreading actively amongst 32 % of new patients. Pre-extensively drug-resistant (pre-XDR) isolates are present in all sites, with Ghana showing the highest proportion (35 % of MDR). In Ghana and Togo, pre-XDR isolates are circulating amongst new patients.

CONCLUSIONS:

West African drug-resistance prevalence poses a previously underestimated, yet serious public health threat, and our estimates obtained differ significantly from previous World Health Organisation (WHO) estimates. Therefore, our data are reshaping current concepts and are essential in informing WHO and public health strategists to implement urgently needed surveillance and control interventions in West Africa.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Tuberculose Extensivamente Resistente a Medicamentos Tipo de estudo: Diagnostic_studies / Guideline / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Tuberculose Extensivamente Resistente a Medicamentos Tipo de estudo: Diagnostic_studies / Guideline / Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2016 Tipo de documento: Article